NOX1

Summary

NOX1 (NADPH oxidase 1, HGNC:7889) is a protein-coding gene on chromosome Xq22.1, encoding NADPH oxidase 1 (Q9Y5S8). NADPH oxidase that catalyzes the generation of superoxide from molecular oxygen utilizing NADPH as an electron donor.

This gene encodes a member of the NADPH oxidase family of enzymes responsible for the catalytic one-electron transfer of oxygen to generate superoxide or hydrogen peroxide. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 27035 — RefSeq curated summary.

At a glance

• Gene–disease (curated): inflammatory bowel disease (Limited, GenCC)
• Clinical variants (ClinVar): 136 total — 1 pathogenic
• Druggable target: yes — 4 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_007052

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7889
Approved symbol	NOX1
Name	NADPH oxidase 1
Location	Xq22.1
Locus type	gene with protein product
Status	Approved
Aliases	NOH1, NOH-1, MOX1, GP91-2, NOH-1L
Ensembl gene	ENSG00000007952
Ensembl biotype	protein_coding
OMIM	300225
Entrez	27035

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 11 protein_coding

ENST00000217885, ENST00000372960, ENST00000372964, ENST00000372966, ENST00000427768, ENST00000865282, ENST00000865283, ENST00000865284, ENST00000865285, ENST00000865286, ENST00000950323

RefSeq mRNA: 3 — MANE Select: NM_007052 NM_001271815, NM_007052, NM_013955

CCDS: CCDS14474, CCDS14475, CCDS65298

Canonical transcript exons

ENST00000372966 — 13 exons

Exon	Start	End
ENSE00000401021	100849772	100849934
ENSE00000401023	100848630	100848754
ENSE00000673714	100849280	100849426
ENSE00001174525	100843324	100844078
ENSE00001602753	100870719	100870814
ENSE00001607924	100851233	100851325
ENSE00001637130	100862669	100862820
ENSE00001653972	100863159	100863243
ENSE00001661840	100850151	100850386
ENSE00001701549	100862392	100862573
ENSE00001702593	100862171	100862303
ENSE00001767233	100863485	100863595
ENSE00003848907	100874095	100874359

Expression profiles

Bgee: expression breadth ubiquitous, 155 present calls, max score 96.58.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1335 / max 53.5514, expressed in 21 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199934	0.0488	18
199936	0.0444	14
199935	0.0300	14
199933	0.0104	5

Top tissues by expression

276 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
rectum	UBERON:0001052	96.58	gold quality
mucosa of sigmoid colon	UBERON:0004993	96.17	gold quality
colonic mucosa	UBERON:0000317	95.75	gold quality
mucosa of transverse colon	UBERON:0004991	91.07	gold quality
transverse colon	UBERON:0001157	83.19	gold quality
ileal mucosa	UBERON:0000331	82.95	gold quality
diaphragm	UBERON:0001103	79.73	gold quality
colonic epithelium	UBERON:0000397	78.72	gold quality
mucosa of urinary bladder	UBERON:0001259	78.25	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.23	silver quality
type B pancreatic cell	CL:0000169	76.35	gold quality
olfactory bulb	UBERON:0002264	76.19	gold quality
large intestine	UBERON:0000059	74.79	gold quality
buccal mucosa cell	CL:0002336	74.51	silver quality
colon	UBERON:0001155	73.85	gold quality
pancreatic ductal cell	CL:0002079	73.74	silver quality
vastus lateralis	UBERON:0001379	72.28	gold quality
tongue squamous epithelium	UBERON:0006919	71.85	gold quality
nasal cavity epithelium	UBERON:0005384	71.31	gold quality
quadriceps femoris	UBERON:0001377	71.24	gold quality
intestine	UBERON:0000160	70.41	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	70.39	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	70.17	gold quality
superficial temporal artery	UBERON:0001614	70.16	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	69.46	gold quality
vermiform appendix	UBERON:0001154	69.42	gold quality
parotid gland	UBERON:0001831	68.72	gold quality
thymus	UBERON:0002370	68.49	gold quality
caecum	UBERON:0001153	68.39	gold quality
cartilage tissue	UBERON:0002418	67.73	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.77

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, ATF1, CDX1, CDX2, GATA6, HIPK2, IRF6, JUN, JUNB, MEF2B, NFE2L2, NFKB, PITX2, SP1, STAT1, STAT3, STAT4, THRA

miRNA regulators (miRDB)

46 targeting NOX1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-4645-3P	99.76	69.33	993
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6757-3P	99.63	66.88	1089
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-582-5P	99.47	70.79	2635
HSA-MIR-12132	99.47	68.90	1341
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-6507-5P	99.36	70.46	2524

Literature-anchored findings (GeneRIF, showing 40)

• Ionomycin-induced neutrophil NADPH oxidase activity is selectively inhibited by the serine protease inhibitor diisopropyl fluorophosphate (PMID:11970839)
• The activity of leukocyte NADPH oxidase: regulation by p47PHOX cysteine and serine residues (PMID:11970841)
• Nox1 partially restores the defective oxidases of gp91phox-deficient PLB-985 leukemia cells and peripheral blood stem cells of X-linked chronic granulomatous disease patients. (PMID:12817011)
• our data strongly implicate Nox1 in redox-mediated signaling related to cellular activation of human keratinocytes at a more advanced stage of transformation. (PMID:12955083)
• NOXO1 and NOXA1 activate Nox1 without the need for agonist activation, and this is mediated in part by binding of the NOXO1 PX domain to membrane lipids. (PMID:14617635)
• Nox1 co-localizes with caveolin in punctate patches on the surface & along the cellular margins of vascular smooth muscle cells. Its role may be correlated with its compartamentalization in specific membrane signaling domains. (PMID:14670934)
• aging-related cell surface NADH oxidase (arNOX) generates superoxide and is inhibited by coenzyme Q (PMID:14674687)
• Cells expressed gp91phox homologs Nox1, Nox2, and Nox4. Keratinocytes expressed Nox distinct from phox isoform of phagocytes. Source of superoxide that may regulate cell proliferation and host defense in skin and oral mucosa. (PMID:15102091)
• NADPH oxidase has a role in Cox-2 inhibition through ROS and GSH/GSSG reduction, and NF-kappaB suppression (PMID:15203187)
• Nox1, in turn, was expressed at only low levels in a small number of patients, but when detected it was present in arteries and veins. (PMID:15256399)
• p22phox directly interacts with Nox1 and Nox4, to form an superoxide-generating NADPH oxidase. (PMID:15322091)
• no appropriate RNA splicing sites were found within Nox1 to account for NOH-1S formation, but repetitive sequence elements bordering the deleted region could promote intramolecular template switching during cDNA synthesis (PMID:15375166)
• human prostate cancer frequently show both increased H(2)O(2) and Nox1 (PMID:15389790)
• NADPH oxidase has a role in fibrillar Abeta1-42 peptide-induced neuronal apoptosis (PMID:15452132)
• Two identified isoforms of human Nox1 may be functionally distinct. (PMID:15708375)
• Nuclear factor (NF)-kappaB was predominantly activated in adenoma and adenocarcinoma cells expressing abundant Nox1, suggesting that Nox1 may stimulate NF-kappaB-dependent antiapoptotic pathways in colon tumors. (PMID:15797632)
• At the immunohistochemical level Nox1 expression was significantly increased in syncytiotrophoblast and endothelial cells in placentas from patients with preeclampsia as compared to gestational age-matched controls. (PMID:15993942)
• activation of tie-2 receptors by Ang-1 triggers the production of ROS through activation of NADPH oxidase (PMID:16049136)
• Results support a potential contribution of Nox1 to mucosal host defense and inflammation in the colon. (PMID:16162660)
• These results suggest that the formation of the complex consisting of Nox1, betaPix, and NoxO1 is likely to be a critical step in EGF-induced ROS generation. (PMID:16329988)
• A study evaluating the relationship between phagocytic NADPH oxidase activity and oxidative stress and atherosclerosis in metabolic syndrome patients is presented. (PMID:16380495)
• Chronic granulomatous disease (CGD) is a genetic disease caused by structural mutations in the enzyme NADPH oxidase that results in severe immunodeficiency. (PMID:16468977)
• Inhibition of alphaIIbbeta3 activation by NAD(P)H oxidase inhibitors and superoxide scavengers was independent of NO/cGMP signaling demonstrating a direct role of platelet NAD(P)H oxidase-generated ROS for integrin alphaIIbbeta3 activation. (PMID:16469512)
• Rac1 regulates both oxidases Nox1 and Nox3 through the Nox activators (PMID:16507994)
• Rac1 activation provides a major trigger that acutely activates Nox1-dependent reactive oxygen species generation (PMID:16636067)
• Rac1 directly participates in Nox1 activation via interacting with Noxa1. (PMID:16762923)
• Data show that GM-CSF and TNF-alpha induce phosphorylation of Ser345 on p47phox, a cytosolic component of NADPH oxidase, in human neutrophils. (PMID:16778989)
• This study identifies a role for p40(phox) and PI(3)P in coupling FcgammaR-mediated phagocytosis to activation of the NADPH oxidase. (PMID:16880255)
• there is a signaling link between the mitochondria and Nox1, which is crucial for the sustained accumulation of ROS and cell death in serum withdrawal-induced signaling (PMID:17015444)
• Nox1 expression and activation inhibited TNF-alpha-induced inhibitor of kappaB kinase (IKK), and NF-kappaB while promoting JNK activation and cell death. (PMID:17079781)
• Deletion of GSTT1 gene might be considered as protective factor for hypertension. (PMID:17182005)
• VHL protein exerts its tumor suppressor action, at least partially, via inhibition of p22phox-based Nox4/Nox1 NADPH oxidase-dependent reactive oxygen species generation (PMID:17200123)
• Potential candidate genes in these regions that have been implicated in diabetic nephropathy and/or renal damage in models of hypertension include CYBA (or P22PHOX) (16q24), NOX1 (10q22), and NOX3 (6q25.1-q26). (PMID:17336700)
• Nox1 has a role in inducing resistance against differentiation-induced cell death (PMID:17460729)
• cortactin and actin have roles in hyperoxia-induced activation of NADPH oxidase and ROS generation in human lung endothelial cells (PMID:17562703)
• UVA activates Nox1-based NADPH oxidase to produce ROS that stimulate PGE2 synthesis, and that Nox1 may be an appropriate target for agents designed to block UVA-induced skin injury. (PMID:17611574)
• NADPH oxidase-derived ROS selectively modulate some but not all the effects of VEGF on endothelial cell phenotypes (PMID:17908694)
• PKA-phosphorylated NoxA1 is a new binding partner of 14-3-3 protein; this forms the basis of a novel mechanism regulating the formation of ROS by Nox1 and, potentially, other NoxA1-regulated Nox family members (PMID:17913709)
• Overexpression of the hNOX1 complex increased the steady-state levels of DNA 8-oxo-7,8-dihydroguanine and caused a threefold increase in the HPRT mutation rate in HeLa cells. (PMID:17963706)
• These data indicate that developmental, tissue-restricted transcription factors play a key role in NOX1 regulation in vivo. (PMID:18005670)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Nox1	ENSMUSG00000031257
rattus_norvegicus	Nox1	ENSRNOG00000048706

Paralogs (6): NOX3 (ENSG00000074771), NOX4 (ENSG00000086991), DUOX1 (ENSG00000137857), DUOX2 (ENSG00000140279), CYBB (ENSG00000165168), NOX5 (ENSG00000255346)

Protein

Protein identifiers

NADPH oxidase 1 — Q9Y5S8 (reviewed: Q9Y5S8)

Alternative names: Mitogenic oxidase 1, NADH/NADPH mitogenic oxidase subunit P65-MOX, NOH-1

All UniProt accessions (4): Q9Y5S8, A6NGA6, H0Y581, Q5H9D4

UniProt curated annotations — full annotation on UniProt →

Function. NADPH oxidase that catalyzes the generation of superoxide from molecular oxygen utilizing NADPH as an electron donor. NADPH oxidase that catalyzes the generation of superoxide from molecular oxygen utilizing NADPH as an electron donor.

Subunit / interactions. NOX1, NOXA1, NOXO1, RAC1 and CYBA forms a functional multimeric complex supporting reactive oxygen species (ROS) production. Interacts with NOXO1. Interacts (via FAD-binding FR-type domain) with ARHGEF7 (via PH domain). The phosphorylated form at Thr-430 interacts with NOXA1 with greater affinity.

Subcellular location. Cell projection. Invadopodium membrane. Cell membrane.

Tissue specificity. Detected in colon, uterus, prostate, and colon carcinoma, but not in peripheral blood leukocytes.

Post-translational modifications. Phosphorylation at Thr-430 mediated by PKC/PRKBC positively regulates its interaction with NOXA1 and enzyme activity.

Disease relevance. Defects in NOX1 may play a role in the pathogenesis of very early onset inflammatory bowel disease (VEOIBD), a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology diagnosed before 6 years of age. VEOIBD is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but the phenotype of children with onset of Crohn disease occurring younger than the age of 10 is predominantly colonic, with a lower risk of ileal disease. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.

Activity regulation. The oxidase activity is potentiated by NOXA1, NOXO1 and RAC1.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y5S8-1	NOH-1L	yes
Q9Y5S8-3	NOH-1LV

RefSeq proteins (3): NP_001258744, NP_008983, NP_039249 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000778	Cyt_b245_heavy_chain	Family
IPR013112	FAD-bd_8	Domain
IPR013121	Fe_red_NAD-bd_6	Domain
IPR013130	Fe3_Rdtase_TM_dom	Domain
IPR017927	FAD-bd_FR_type	Domain
IPR017938	Riboflavin_synthase-like_b-brl	Homologous_superfamily
IPR039261	FNR_nucleotide-bd	Homologous_superfamily
IPR050369	RBOH/FRE	Family

Pfam: PF01794, PF08022, PF08030

Catalyzed reactions (Rhea), 1 shown:

• NADPH + 2 O2 = 2 superoxide + NADP(+) + H(+) (RHEA:63180)

UniProt features (31 total): topological domain 7, transmembrane region 6, binding site 5, sequence variant 4, domain 2, glycosylation site 2, chain 1, region of interest 1, modified residue 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y5S8-F1	90.43	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5): 101 (axial binding residue); 115 (axial binding residue); 209 (axial binding residue); 221 (axial binding residue); 338–344

Post-translational modifications (1): 430

Glycosylation sites (2): 162, 236

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-5668599	RHO GTPases Activate NADPH Oxidases
R-HSA-9013149	RAC1 GTPase cycle
R-HSA-9013423	RAC3 GTPase cycle
R-HSA-9673324	WNT5:FZD7-mediated leishmania damping

MSigDB gene sets: 159 (showing top): GOBP_REGULATION_OF_BLOOD_PRESSURE, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_INFLAMMATORY_RESPONSE, GOBP_NADPPLUS_METABOLIC_PROCESS, GOBP_PLASMA_MEMBRANE_ORGANIZATION, GOBP_REGULATION_OF_SYSTEMIC_ARTERIAL_BLOOD_PRESSURE, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, GOBP_SUPEROXIDE_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOMF_GTPASE_BINDING, GOBP_MUSCLE_CELL_PROLIFERATION, PUJANA_CHEK2_PCC_NETWORK, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, WEI_MYCN_TARGETS_WITH_E_BOX

GO Biological Process (24): angiogenesis (GO:0001525), regulation of systemic arterial blood pressure by renin-angiotensin (GO:0003081), NADP+ metabolic process (GO:0006739), defense response (GO:0006952), inflammatory response (GO:0006954), signal transduction (GO:0007165), JNK cascade (GO:0007254), regulation of blood pressure (GO:0008217), positive regulation of cell population proliferation (GO:0008284), intrinsic apoptotic signaling pathway in response to oxidative stress (GO:0008631), positive regulation of vascular endothelial growth factor production (GO:0010575), cell migration (GO:0016477), extracellular matrix organization (GO:0030198), superoxide anion generation (GO:0042554), hydrogen peroxide metabolic process (GO:0042743), positive regulation of integrin biosynthetic process (GO:0045726), respiratory burst (GO:0045730), positive regulation of JNK cascade (GO:0046330), positive regulation of smooth muscle cell proliferation (GO:0048661), cellular response to hyperoxia (GO:0071455), oxygen metabolic process (GO:0072592), positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway (GO:1902177), MAPK cascade (GO:0000165), positive regulation of MAPK cascade (GO:0043410)

GO Molecular Function (9): NAD(P)H oxidase H2O2-forming activity (GO:0016174), superoxide-generating NAD(P)H oxidase activity (GO:0016175), small GTPase binding (GO:0031267), metal ion binding (GO:0046872), NADP binding (GO:0050661), superoxide-generating NADPH oxidase activity (GO:0106292), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on NAD(P)H, oxygen as acceptor (GO:0050664)

GO Cellular Component (8): early endosome (GO:0005769), plasma membrane (GO:0005886), cell projection (GO:0042995), NADPH oxidase complex (GO:0043020), cytoplasm (GO:0005737), endosome (GO:0005768), membrane (GO:0016020), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
RHO GTPase cycle	2
RHO GTPase Effectors	1
Killing mechanisms	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
oxidoreductase activity, acting on NAD(P)H, oxygen as acceptor	2
blood vessel morphogenesis	1
anatomical structure formation involved in morphogenesis	1
regulation of systemic arterial blood pressure by hormone	1
purine nucleotide metabolic process	1
nicotinamide nucleotide metabolic process	1
response to stress	1
defense response	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
MAPK cascade	1
blood circulation	1
regulation of biological quality	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
intrinsic apoptotic signaling pathway	1
positive regulation of cytokine production	1
vascular endothelial growth factor production	1
regulation of vascular endothelial growth factor production	1
cell motility	1
extracellular structure organization	1
external encapsulating structure organization	1
superoxide metabolic process	1
reactive oxygen species metabolic process	1
positive regulation of macromolecule biosynthetic process	1
integrin biosynthetic process	1
regulation of integrin biosynthetic process	1
positive regulation of cellular component organization	1
metabolic process	1
JNK cascade	1
positive regulation of MAPK cascade	1
regulation of JNK cascade	1
positive regulation of cell population proliferation	1
smooth muscle cell proliferation	1
regulation of smooth muscle cell proliferation	1

Protein interactions and networks

STRING

2044 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NOX1	CYBA	P13498	999
NOX1	NCF1	P14598	999
NOX1	NOXO1	Q8NFA2	999
NOX1	NOXA1	Q86UR1	998
NOX1	NCF2	P19878	998
NOX1	NCF4	Q15080	991
NOX1	NOX5	Q96PH1	986
NOX1	DUOX1	Q9NRD9	985
NOX1	NOX4	Q9NPH5	984
NOX1	CYBB	P04839	983
NOX1	NOX3	Q9HBY0	982
NOX1	TRADD	Q15628	962
NOX1	DUOX2	Q9NRD8	952
NOX1	AKT1	P31749	947
NOX1	TNFRSF1A	P19438	891

IntAct

21 interactions, top by confidence:

A	B	Type	Score
TBXA2R	NOX1	psi-mi:“MI:0915”(physical association)	0.560
TNFRSF1A	CYBB	psi-mi:“MI:0914”(association)	0.350
NOX1	RHBDD1	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
NOX1	RAB34	psi-mi:“MI:0914”(association)	0.350
AKT1	NOX1	psi-mi:“MI:2364”(proximity)	0.270
FBXW7	NOX1	psi-mi:“MI:2364”(proximity)	0.270
NOX1	SMAD4	psi-mi:“MI:2364”(proximity)	0.270
SPOP	NOX1	psi-mi:“MI:2364”(proximity)	0.270
NOX1	SPOP	psi-mi:“MI:2364”(proximity)	0.270
NOX1	TP53	psi-mi:“MI:2364”(proximity)	0.270
NOX1	PTEN	psi-mi:“MI:2364”(proximity)	0.270
NOX1	EGFR	psi-mi:“MI:2364”(proximity)	0.270
NOX1	BRAF	psi-mi:“MI:2364”(proximity)	0.270
NOX1	TBXA2R	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (15): PPP2R3B (Affinity Capture-MS), RHBDD1 (Affinity Capture-MS), NOX1 (Proximity Label-MS), NOX1 (Reconstituted Complex), ARHGEF7 (Reconstituted Complex), NOXO1 (Reconstituted Complex), NOXA1 (Reconstituted Complex), NOX1 (Affinity Capture-Western), NOX1 (Two-hybrid), NOX1 (Affinity Capture-MS), PPP2R3B (Affinity Capture-MS), RAB34 (Affinity Capture-MS), NOX1 (Affinity Capture-Western), NOX1 (Reconstituted Complex), NOX1 (Affinity Capture-Western)

ESM2 similar proteins: A0JNC1, A2VE61, A6QL84, A7YY49, B2RZ37, O15260, O15431, O57590, O95674, P31064, Q00765, Q06400, Q0VCK9, Q0X0A5, Q3KNM2, Q3T126, Q3ZC24, Q5M7T4, Q5R705, Q5R7B1, Q5R9I4, Q5R9M4, Q5RBJ7, Q5RE33, Q5ZJ41, Q5ZKJ0, Q64310, Q6DD32, Q6GM44, Q6P360, Q6P3N5, Q7SZQ7, Q800K9, Q8BG21, Q8C407, Q8R1Z9, Q91ZQ0, Q940S0, Q96GC9, Q96KA5

Diamond homologs: F4I4K7, O48538, O81211, P92949, Q2HXK9, Q2HXL0, Q3KTM0, Q5ZAJ0, Q672K1, Q6J2K5, Q75CQ8, Q86GL4, Q8CIZ9, Q8RWS6, Q8VY13, Q8W110, Q948U0, Q9FLW2, Q9LMM2, Q9SBI0, Q9SUT8, Q9XYS3, Q9Y5S8, O46522, O81210, P04839, P52649, Q5R5C5, Q61093, Q672J9, Q924V1, Q948T9, Q95L74, Q9FIJ0, Q9HBY0, Q9JHI8, Q9NPH5, Q9SW17, Q9WV87, O81209

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
NOXA1	“up-regulates activity”	NOX1	binding
NOX1	up-regulates	ROS
NOX1	“up-regulates quantity”	superoxide	“chemical modification”
PRKCB	“up-regulates activity”	NOX1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 14 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of apoptotic process	5	13.4×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

136 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	64
Likely benign	16
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3770226	GRCh37/hg19 Xq21.33-22.1(chrX:96380000-100120000)x1	Pathogenic

SpliceAI

1727 predictions. Top by Δscore:

Variant	Effect	Δscore
X:100849273:GACTC:G	donor_loss	1.0000
X:100849274:ACTC:A	donor_loss	1.0000
X:100849275:CTCAC:C	donor_loss	1.0000
X:100849276:TCA:T	donor_loss	1.0000
X:100849277:CACAA:C	donor_loss	1.0000
X:100849278:A:AC	donor_gain	1.0000
X:100849278:ACA:A	donor_loss	1.0000
X:100849279:C:CC	donor_gain	1.0000
X:100849279:CA:C	donor_gain	1.0000
X:100849279:CAAT:C	donor_gain	1.0000
X:100849279:CAATA:C	donor_gain	1.0000
X:100849329:A:AC	donor_gain	1.0000
X:100849330:C:CC	donor_gain	1.0000
X:100849422:TAGAT:T	acceptor_gain	1.0000
X:100849424:GAT:G	acceptor_gain	1.0000
X:100849427:C:CC	acceptor_gain	1.0000
X:100849435:A:T	acceptor_gain	1.0000
X:100849767:TATA:T	donor_loss	1.0000
X:100849769:TA:T	donor_loss	1.0000
X:100849771:C:G	donor_loss	1.0000
X:100849930:CAATC:C	acceptor_gain	1.0000
X:100849933:TCC:T	acceptor_loss	1.0000
X:100849935:C:CC	acceptor_gain	1.0000
X:100849936:T:C	acceptor_loss	1.0000
X:100850279:C:CT	acceptor_gain	1.0000
X:100851326:C:CC	acceptor_gain	1.0000
X:100862165:TCTTA:T	donor_loss	1.0000
X:100862166:CTTAC:C	donor_loss	1.0000
X:100862167:TTA:T	donor_loss	1.0000
X:100862168:TAC:T	donor_loss	1.0000

AlphaMissense

3733 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:100850272:G:C	H338D	0.994
X:100843955:A:C	F564L	0.991
X:100843955:A:T	F564L	0.991
X:100843957:A:G	F564L	0.991
X:100849920:C:T	G383D	0.988
X:100850203:A:G	W361R	0.988
X:100850203:A:T	W361R	0.988
X:100850264:A:C	F340L	0.988
X:100850264:A:T	F340L	0.988
X:100850266:A:G	F340L	0.988
X:100848670:A:G	W510R	0.987
X:100848670:A:T	W510R	0.987
X:100844060:G:C	F529L	0.985
X:100844060:G:T	F529L	0.985
X:100844062:A:G	F529L	0.985
X:100849414:A:G	W437R	0.985
X:100849414:A:T	W437R	0.985
X:100849913:A:C	F385L	0.985
X:100849913:A:T	F385L	0.985
X:100849915:A:G	F385L	0.985
X:100862451:G:C	F204L	0.985
X:100862451:G:T	F204L	0.985
X:100862453:A:G	F204L	0.985
X:100849836:G:T	A411D	0.983
X:100850201:C:A	W361C	0.983
X:100850201:C:G	W361C	0.983
X:100849901:A:C	S389R	0.982
X:100849901:A:T	S389R	0.982
X:100849903:T:G	S389R	0.982
X:100851261:C:G	R290P	0.982

dbSNP variants (sampled 300 via entrez): RS1000093592 (X:100875568 AC>A), RS1000272898 (X:100862880 G>A), RS1000856061 (X:100870919 T>C), RS1000991488 (X:100871288 C>T), RS1001043781 (X:100851224 A>G), RS1001052549 (X:100847527 G>A), RS1001157026 (X:100864946 T>C,G), RS1001211433 (X:100858246 T>A,C), RS1001265643 (X:100852396 GA>G), RS1001400047 (X:100847420 A>G), RS1001438149 (X:100864187 G>T), RS1001997390 (X:100873756 G>C,T), RS1002338099 (X:100870370 T>G), RS1003013629 (X:100864023 A>C), RS1003077138 (X:100844681 C>T)

Disease associations

OMIM: gene MIM:300225 | disease phenotypes: MIM:606159

GenCC curated gene-disease

Disease	Classification	Inheritance
inflammatory bowel disease	Limited	X-linked

Mondo (2): neuroferritinopathy (MONDO:0011638), inflammatory bowel disease (MONDO:0005265)

Orphanet (1): Neuroferritinopathy (Orphanet:157846)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D015212	Inflammatory Bowel Diseases	C06.405.205.731; C06.405.469.432
C548080	Neuroferritinopathy (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1287628 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

4 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 146,987 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL51085	EBSELEN	3	13,237
CHEMBL4303187	SETANAXIB	2	811
CHEMBL4650894	ISUZINAXIB	2	93
CHEMBL828	PHENOTHIAZINE	2	132,846

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — NADPH oxidases

Most potent curated ligand interactions (5 total), top 5:

Ligand	Action	Affinity	Parameter
compound 7c [PMID: 22041175]	Inhibition	7.0	pKi
setanaxib	Inhibition	6.85	pKi
GKT136901	Inhibition	6.8	pKi
NSC 780521	Inhibition	5.99	pIC50
GLX351322	Inhibition	4.4	pIC50

Binding affinities (BindingDB)

85 measured of 93 human assays (93 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
4-(4,5-diphenyl-1,3-dihydroimidazol-2-ylidene)-2-methoxy-cyclohexa-2,5-dien-1-one	IC50	10 nM
N-[5-(3-fluoro-4-pyridinyl)-1,3,4-thiadiazol-2-yl]-3-methoxy-4-[(1S)-1-pyridin-2-ylethoxy]benzamide	KI	13 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-[(4-fluorophenyl)methoxy]-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	14 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-(6,7-dihydro-5H-cyclopenta[b]pyridin-5-yloxy)-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	15 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-(1-phenylethoxy)-3-(piperidin-4-ylmethoxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	18 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-(2-methoxyethylamino)-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	18 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-(oxan-4-ylmethylamino)-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	18 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-[(1-methylpiperidin-4-yl)methylamino]-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	19 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
N-[5-(3-fluoro-4-pyridinyl)-1,3,4-thiadiazol-2-yl]-4-[(1R)-2-hydroxy-1-phenylethoxy]-3-methoxybenzamide	KI	19 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-[2-(dimethylamino)ethylamino]-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	21 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-[(1R)-2-hydroxy-1-phenylethoxy]-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	22 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-[(1R)-2-(dimethylamino)-1-phenylethoxy]-N-[5-(3-fluoro-4-pyridinyl)-1,3,4-thiadiazol-2-yl]-3-methoxybenzamide	KI	22 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-(2,3-dihydro-1H-inden-2-yloxy)-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	22 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-[(1R)-1-(4-fluorophenyl)-2-hydroxyethoxy]-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	24 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-[(1R)-2-(dimethylamino)-1-(4-fluorophenyl)ethoxy]-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	25 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-[[(1R)-2,3-dihydro-1H-inden-1-yl]oxy]-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	27 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
3-methoxy-4-[(1S)-1-phenyl-3-pyrrolidin-1-ylpropoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	29 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-[3-(dimethylamino)propylamino]-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	31 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
3-methoxy-4-[(4-methoxyphenyl)methoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	32 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
6-[3-(4-methoxyphenyl)propoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	32 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-[cyclopropyl(phenyl)methoxy]-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	33 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-methoxy-6-[(1S)-1-pyridin-2-ylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	35 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-(indol-1-ylmethyl)-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	35 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
3-[2-(dimethylamino)ethoxy]-4-(1-phenylethoxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	37 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
6-[(1R)-2-(dimethylamino)-1-phenylethoxy]-5-methoxy-N-(5-pyrimidin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	37 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-methyl-6-[(1R)-2-morpholin-4-yl-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	37 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-(oxan-4-ylmethoxy)-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	38 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)-4-(1,2,3,4-tetrahydronaphthalen-1-yloxy)benzamide	KI	38 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-(2,3-dihydro-1-benzofuran-3-yloxy)-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	38 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
6-(1-phenylpropan-2-yloxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	45 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
3-methoxy-4-[(2S)-1-phenylpropan-2-yl]oxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	46 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
6-(2,3-dihydro-1H-inden-1-yloxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	47 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-[(1S)-1-(4-fluorophenyl)-2-hydroxyethoxy]-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	47 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
3-methoxy-4-[(1R)-1-phenyl-2-pyrrolidin-1-ylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	49 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-(2-hydroxyethylamino)-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	51 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-[(2-fluorophenyl)methoxy]-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	52 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-(4-methylpiperazin-1-yl)-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	55 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
3-methoxy-4-(2-methoxy-1-phenylethoxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	55 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
6-[(1R)-2-(3,3-difluoropyrrolidin-1-yl)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	55 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-(4-methylpiperazin-1-yl)-6-phenylmethoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	62 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-chloro-6-[(1R)-2-hydroxy-2-methyl-1-phenylpropoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	64 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-[(1-methylimidazol-4-yl)methylamino]-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	66 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
6-(1-phenylpropoxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	71 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-(2-morpholin-4-ylethylamino)-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	72 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
3-(2-methoxyethoxy)-4-(1-phenylethoxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	74 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
4-[(5-cyclopropyl-1,2-oxazol-3-yl)methoxy]-3-methoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	74 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
5-[(1-methylpiperidin-4-yl)amino]-6-[(1S)-1-phenylethoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	75 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
3-methoxy-4-phenylmethoxy-N-(5-pyrimidin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	75 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
2-methyl-6-phenylmethoxy-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)pyridine-3-carboxamide	KI	77 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors
3-methoxy-4-[(5-methyl-1,2-oxazol-3-yl)methoxy]-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)benzamide	KI	78 nM	US-10130619: Amido thiadiazole derivatives as NADPH oxidase inhibitors

ChEMBL bioactivities

196 potent at pChembl≥5 of 224 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.00	IC50	10	nM	CHEMBL441558
7.89	Ki	13	nM	CHEMBL5778172
7.85	Ki	14	nM	CHEMBL6033400
7.82	Ki	15	nM	CHEMBL5846478
7.75	Ki	18	nM	CHEMBL5879030
7.75	Ki	18	nM	CHEMBL5746246
7.75	Ki	18	nM	CHEMBL5908474
7.72	IC50	19	nM	CHEMBL5435186
7.72	Ki	19	nM	CHEMBL5945219
7.72	Ki	19	nM	CHEMBL5904070
7.68	Ki	21	nM	CHEMBL6054445
7.66	Ki	22	nM	CHEMBL5963851
7.66	Ki	22	nM	CHEMBL6046507
7.66	Ki	22	nM	CHEMBL5754462
7.62	Ki	24	nM	CHEMBL6026156
7.60	Ki	25	nM	CHEMBL6055046
7.57	Ki	27	nM	CHEMBL6007454
7.54	Ki	29	nM	CHEMBL5897477
7.51	Ki	31	nM	CHEMBL5976195
7.50	Ki	32	nM	CHEMBL5758710
7.50	Ki	32	nM	CHEMBL6009135
7.48	Ki	33	nM	CHEMBL5965137
7.46	Ki	35	nM	CHEMBL5851649
7.46	Ki	35	nM	CHEMBL6024969
7.43	Ki	37	nM	CHEMBL5992458
7.43	Ki	37	nM	CHEMBL5760855
7.43	Ki	37	nM	CHEMBL5774032
7.42	Ki	38	nM	CHEMBL5944298
7.42	Ki	38	nM	CHEMBL5981152
7.42	Ki	38	nM	CHEMBL5927335
7.36	IC50	44	nM	CHEMBL1323615
7.35	Ki	45	nM	CHEMBL6057480
7.34	Ki	46	nM	CHEMBL6025280
7.33	Ki	47	nM	CHEMBL6015387
7.33	Ki	47	nM	CHEMBL5877467
7.32	IC50	48	nM	CHEMBL1567692
7.31	Ki	49	nM	CHEMBL5771168
7.29	Ki	51	nM	CHEMBL6034297
7.28	Ki	52	nM	CHEMBL5800948
7.28	IC50	53	nM	CHEMBL1331532
7.27	IC50	54	nM	CHEMBL1401860
7.26	Ki	55	nM	CHEMBL5842287
7.26	Ki	55	nM	CHEMBL5810313
7.26	Ki	55	nM	CHEMBL6052961
7.21	Ki	62	nM	CHEMBL5771404
7.19	Ki	64	nM	CHEMBL5988311
7.18	Ki	66	nM	CHEMBL5949798
7.15	Ki	71	nM	CHEMBL5844047
7.14	Ki	72	nM	CHEMBL6043267
7.13	Ki	74	nM	CHEMBL6038093

PubChem BioAssay actives

40 with measured affinity, of 69 total; 40 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(4R)-4-amino-5-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-6-amino-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid	2013315: Inhibition of NOX1 (unknown origin) expressed in HT 29 cells assessed as inhibition of PMA-induced hydrogen peroxide production pre-incubated for 15 mins and followed by PMA stimulation and measured after 10 mins by Amplex Red based analysis	ic50	0.0190	uM
4-(2-chlorophenyl)-13-[(2-chlorophenyl)methyl]-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.0870	uM
4-(2-chlorophenyl)-13-[(4-chlorophenyl)methyl]-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.0950	uM
13-benzyl-4-(2-chlorophenyl)-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.1010	uM
4-(2-chlorophenyl)-13-[(3-chlorophenyl)methyl]-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.1040	uM
4-(2-chlorophenyl)-13-(pyridin-2-ylmethyl)-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.1130	uM
4-(2-chlorophenyl)-13-[(3-methoxyphenyl)methyl]-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.1130	uM
4-(2-chlorophenyl)-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.1190	uM
4-(2-chlorophenyl)-13-[(2-methoxyphenyl)methyl]-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.1330	uM
2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6-dione	2013292: Binding affinity to human NOX1 assessed as inhibition constant	ki	0.1400	uM
tert-butyl 4-(2-chlorophenyl)-3,8-dioxo-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-13-carboxylate	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.1480	uM
2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6-dione	537291: Inhibition of human NOX1 overexpressed in human PMN cell membrane assessed as ROS production by cell free assay in presence of NADPH	ki	0.1650	uM
4-(2-chlorophenyl)-12-oxa-4,5,9-triazatricyclo[7.4.0.02,6]trideca-1,6-diene-3,8-dione	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.1730	uM
4-(2-chlorophenyl)-13-[(4-methoxyphenyl)methyl]-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.1840	uM
4-(2-chlorophenyl)-13-(furan-3-ylmethyl)-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.2000	uM
4-(2-chlorophenyl)-13-(pyridin-3-ylmethyl)-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.2080	uM
4-(2-methoxyphenyl)-13-[(3-methoxyphenyl)methyl]-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.2120	uM
4-(2-methoxyphenyl)-13-(pyridin-2-ylmethyl)-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.2170	uM
13-benzyl-4-(2-methoxyphenyl)-4,5,9,13-tetrazatricyclo[7.5.0.02,6]tetradeca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.2180	uM
8-iodoniatricyclo[7.4.0.02,7]trideca-1(13),2,4,6,9,11-hexaene chloride	2013273: Inhibition of human NOX1 expressed in CHO cells assessed as inhibition of PMA-induced hydrogen peroxide production pretreated for 15 mins followed by PMA stimulation and measured after 10 mins by Amplex Red based fluorescence analysis	ic50	0.2400	uM
1-(10H-phenothiazin-2-yl)ethanone	2013295: Inhibition of human NOX1 transfected in HEK293T cells incubated for 16 hrs and measured after 30 mins by luminol-chemiluminescence based assay	ic50	0.2500	uM
(5Z)-3-(3-chlorophenyl)-5-[[4-(dimethylamino)phenyl]methylidene]-1-methyl-2-sulfanylideneimidazolidin-4-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	0.3500	uM
12-benzyl-4-(2-chlorophenyl)-4,5,9,12-tetrazatricyclo[7.4.0.02,6]trideca-1,6-diene-3,8-dione;hydrochloride	635429: Antagonist activity at human NOX1 expressed in CHO cell membrane coexpressing tetracylin repressor assessed as inhibition of ROS production after 20 mins by cell-free amplex red assay	ki	0.3980	uM
(2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid	2013273: Inhibition of human NOX1 expressed in CHO cells assessed as inhibition of PMA-induced hydrogen peroxide production pretreated for 15 mins followed by PMA stimulation and measured after 10 mins by Amplex Red based fluorescence analysis	ic50	0.4100	uM
2-phenyl-1,2-benzoselenazol-3-one	2013278: Inhibition of human NOX1 expressed in HEK cells assessed as inhibition of ionomycin-induced hydrogen peroxide production pre-incubated for 15 mins followed by ionomycin stimulation and measured after 10 mins by Fluorescence polarization assay	ic50	0.5000	uM
2-(3-benzyltriazolo[4,5-d]pyrimidin-7-yl)sulfanyl-1,3-benzoxazole	2013281: Inhibition of human NOX1 transfected in CHO cells assessed as PMA-induced hydrogen peroxide pre-incubated for 10 and measured after 15 mins by Amplex-red based fluorescence assay	ic50	0.5000	uM
(5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-1-methyl-3-(4-methylphenyl)-2-sulfanylideneimidazolidin-4-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	1.0200	uM
5-phenyl-4-propyl-2-pyridin-2-yl-1H-pyrazol-3-one	2013288: Binding affinity to human NOX1 assessed as reduction in ROS production using lucigenin as substrate in presence of NADPH by chemiluminescence base assay	ki	1.0800	uM
5-phenyl-2-pyridin-2-yl-1H-pyrazol-3-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	1.4500	uM
(5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-1-methyl-3-phenyl-2-sulfanylideneimidazolidin-4-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	1.9500	uM
N-[1-hydroxy-3-[2-[2-(4-hydroxyphenyl)-6-methoxy-2,3-dihydro-1-benzofuran-3-yl]-1H-indol-3-yl]propan-2-yl]acetamide	2013299: Inhibition of NOX1 (unknown origin) expressed in HEK293 cells assessed as ROS production incubated for 45 mins and measured after 5 mins by chemiluminescent analysis	ic50	2.0000	uM
(5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-3-(4-ethylphenyl)-1-methyl-2-sulfanylideneimidazolidin-4-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	4.3900	uM
(5Z)-3-(2,3-dihydro-1H-inden-5-yl)-5-[(2,4-dihydroxyphenyl)methylidene]-1-methyl-2-sulfanylideneimidazolidin-4-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	6.5800	uM
(5Z)-3-(2,3-dihydro-1H-inden-5-yl)-5-[(2,3-dihydroxyphenyl)methylidene]-1-methyl-2-sulfanylideneimidazolidin-4-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	6.6300	uM
2-N-(3,4-dimethylphenyl)-6-[[4-(4-methylphenyl)piperazin-1-yl]methyl]-1,3,5-triazine-2,4-diamine	2013308: Inhibition of NOX1 (unknown origin)	ic50	7.0000	uM
2-N-(3,4-dimethylphenyl)-6-[4-(4-methylphenyl)piperazin-1-yl]-1,3,5-triazine-2,4-diamine	1917069: Inhibition of human NOX1	ic50	7.0000	uM
(5Z)-3-cyclohexyl-5-[(2,3-dihydroxyphenyl)methylidene]-1-methyl-2-sulfanylideneimidazolidin-4-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	7.3900	uM
(5Z)-3-(3-chlorophenyl)-5-[(2,3-dihydroxyphenyl)methylidene]-1-methyl-2-sulfanylideneimidazolidin-4-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	7.6500	uM
(5Z)-3-(2,3-dihydro-1H-inden-5-yl)-5-[[4-(dimethylamino)phenyl]methylidene]-1-methyl-2-sulfanylideneimidazolidin-4-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	8.0400	uM
(5Z)-5-[(2,4-dihydroxyphenyl)methylidene]-3-(4-ethylphenyl)-1-methyl-2-sulfanylideneimidazolidin-4-one	1314096: Inhibition of human NOX1 expressed in Drosophila DUOX knockdown model assessed as decrease in ROS production by lucigenin chemiluminescence assay	ki	8.4000	uM

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Lipopolysaccharides	increases expression, increases reaction, affects localization, affects reaction, increases phosphorylation (+1 more)	4
diphenyleneiodonium	increases expression, decreases activity, increases abundance, decreases response to substance, affects cotreatment (+1 more)	3
bisphenol A	affects cotreatment, decreases methylation, increases expression, decreases reaction	2
chromium hexavalent ion	increases expression	2
Palmitic Acid	decreases reaction, increases expression	2
diminazene aceturate	decreases expression	1
geraniol	decreases reaction, increases expression	1
o,p’-DDT	increases expression, decreases reaction	1
mono-(2-ethylhexyl)phthalate	increases expression	1
sodium arsenite	affects expression	1
butyraldehyde	decreases expression	1
nickel chloride	increases expression	1
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	affects reaction, affects response to substance, increases expression, decreases activity, decreases reaction (+2 more)	1
acetovanillone	increases expression, affects cotreatment, decreases reaction	1
acteoside	decreases activity	1
carvacrol	affects binding	1
crenatoside	decreases activity	1
U 0126	decreases reaction, increases expression, decreases expression	1
dalcetrapib	increases expression	1
3-(4-methylphenylsulfonyl)-2-propenenitrile	decreases expression	1
torcetrapib	increases expression	1
abrine	decreases expression	1
alisol B 23-acetate	decreases reaction, increases expression	1
anacetrapib	increases expression	1
ruxolitinib	affects cotreatment, increases expression	1
rossicaside B	decreases activity	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	increases expression, decreases reaction	1
Arsenic Trioxide	affects cotreatment, increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1

ChEMBL screening assays

32 unique, capped per target: 20 binding, 12 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1286988	Binding	Inhibition of human NOX1 overexpressed in human PMN cell membrane assessed as ROS production by cell free assay in presence of NADPH	First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. — J Med Chem
CHEMBL1613816	Functional	PUBCHEM_BIOASSAY: Late-stage luminescence-based cell-based dose response assay to identify inhibitors of NADPH oxidase 1 (NOX1): Synthesized analogs. (Class of assay: confirmatory) [Related pubchem assays: 1796 (Summary AID (NOX1 inhibitors	PubChem BioAssay data set

Cellosaurus cell lines

2 cell lines: 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9LJ	Ubigene HEK293 NOX1 KO	Transformed cell line	Female
CVCL_ZL50	NOX1-HEK293	Transformed cell line	Female

Clinical trials (associated diseases)

301 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00167882	PHASE4	COMPLETED	The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels
NCT00205062	PHASE4	TERMINATED	Positron Emission Tomography (PET)-Computed Tomography (CT) in Inflammatory Bowel Disease (IBD)
NCT00567593	PHASE4	COMPLETED	Gene Regulation by Thiazolidinediones
NCT00746395	PHASE4	COMPLETED	Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
NCT01034358	PHASE4	COMPLETED	Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
NCT01056913	PHASE4	COMPLETED	NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery
NCT01067547	PHASE4	COMPLETED	A Trial of Iron Replacement in Patients With Iron Deficiency.
NCT01341808	PHASE4	COMPLETED	Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients
NCT01908283	PHASE4	COMPLETED	Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease
NCT01934088	PHASE4	COMPLETED	Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy
NCT02162862	PHASE4	COMPLETED	Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease
NCT02248337	PHASE4	COMPLETED	Low Volume Colon Preparation for IBD
NCT02281799	PHASE4	WITHDRAWN	Thiopurine Induced Pancreatitis in IBD Patients
NCT02392286	PHASE4	TERMINATED	Corticosteroid Dosage for Crohn’s Disease Flare
NCT02437591	PHASE4	COMPLETED	Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
NCT02453776	PHASE4	COMPLETED	Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab
NCT02461758	PHASE4	COMPLETED	Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients
NCT02566889	PHASE4	TERMINATED	An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease
NCT02774057	PHASE4	UNKNOWN	Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD
NCT02806206	PHASE4	UNKNOWN	Prucalopride Prior to Small Bowel Capsule Endoscopy
NCT02946203	PHASE4	COMPLETED	Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients
NCT02994836	PHASE4	COMPLETED	GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )
NCT03220841	PHASE4	UNKNOWN	Stricture Definition and Treatment (STRIDENT) Drug Therapy Study
NCT03351972	PHASE4	COMPLETED	Differences in Preparation for Small Bowel Capsule Endoscopy
NCT03466983	PHASE4	COMPLETED	A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease
NCT03591770	PHASE4	TERMINATED	Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib
NCT03629379	PHASE4	COMPLETED	Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
NCT03723447	PHASE4	COMPLETED	Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
NCT03798691	PHASE4	COMPLETED	Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab
NCT03860012	PHASE4	UNKNOWN	Folic Acid in Pediatric Inflammatory Bowel Disease
NCT03885713	PHASE4	COMPLETED	Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
NCT03917303	PHASE4	RECRUITING	Control Crohn Safe Trial
NCT04045782	PHASE4	COMPLETED	Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders
NCT04304950	PHASE4	COMPLETED	Chronotherapy in Inflammatory Bowel Disease
NCT04626947	PHASE4	TERMINATED	Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
NCT04646187	PHASE4	ENROLLING_BY_INVITATION	De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease
NCT04835506	PHASE4	ACTIVE_NOT_RECRUITING	Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
NCT04982172	PHASE4	COMPLETED	Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases
NCT05180175	PHASE4	COMPLETED	The Nordic IBD Treatment Strategy Trial
NCT05280405	PHASE4	UNKNOWN	Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study